Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05046158
Other study ID # U-C-TPD-2021-01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 16, 2021
Est. completion date December 31, 2023

Study information

Verified date June 2023
Source ULURU Inc.
Contact Vaidehi Shah, MBA
Phone 646-431-9455
Email vshah@altrazeal.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase IV, randomized, prospective, multi-center, open-label, comparison of transforming powder dressing to standard of care dressing for healing diabetic foot ulcers.


Description:

Diabetic men and women aged 18-89 years, who have a diabetic foot ulcer present for a minimum of 30 days will be considered for the study. Subjects will be randomized to either standard of care wound dressings or transforming powder dressing. Half of the subjects will receive standard of care dressings, and the other half will receive transforming powder dressing in a 1:1 randomization process at each of the study sites. Subjects will present to the study center weekly for up to 12 weeks (less time if the wound heals prior to 12 weeks). The last study visit occurs 12 weeks after the End of Study visit.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria: - 18-89 years old - Diagnosed with diabetes Mellitus; hemoglobin A1C < 12% - Diabetic foot ulcer present for minimum 30 days (Wagner grade 1 or 2 classification) - Wound drainage is minimal or moderate - No clinically active wound infection - Able and willing to provide consent - Has not participated in another research trial within 3 months of enrollment. Exclusion Criteria: - Unable to keep weekly research appointments - Unable or unwilling to use offloading device if recommended - Wounds with large amount (high) drainage - Active gangrene - Wounds impending surgical intervention (including revascularization or plastic surgery) - Untreated osteomyelitis - Soft tissue infection (can be enrolled once infection is cleared) - Active Charcot arthropathy - BMI >45kg/m2 - History of AIDS - History of organ transplant or impending transplant - End stage renal disease requiring dialysis - Decompensated hepatic or cardiac disease - Select autoimmune diseases - Lymphedema - Oral steroid use in last 3 months - Venous stasis disease - Active malignancy (cancer) - Unable to sign consent - Active alcohol or substance abuse - Pregnant or lactating women - Insufficient vascular flow to heal a wound - Hemoglobin A1C >12%

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Transforming Powder Dressing
Altrazeal transforming powder dressing is methacrylate-based powder dressing made from the same materials used in the production of contact lenses. Upon hydration, the powder transforms into a moist, non-occlusive barrier that covers and protects the wound from exogenous bacteria while helping manage exudate through vapor transpiration.
Other:
Standard of care topical wound agents and dressings
Standard wound dressings such as gauze or foams. Moisture regulating topical agents may also be used to prepare the wound bed.

Locations

Country Name City State
United States MedStar Good Samaritan Hospital Baltimore Maryland
United States VA Maryland Health Care System Baltimore Maryland
United States Bronx Foot Care Bronx New York
United States James J. Peters VA Medical Center Bronx New York
United States Dallas Veteran's Administration Medical Center Dallas Texas
United States Baylor College of Medicine Clinic Hospital McNair (MDHP) BCM390 Houston Texas
United States Northwell Health Wound Healing Center Lake Success New York
United States MedStar Franklin Square Rossville Maryland
United States VA Hudson Valley HealthCare System Wappingers Falls New York
United States MedStar Georgetown University Hospital Washington District of Columbia
United States MedStar Washington Hospital Center Washington District of Columbia
United States AdventHealth Medical Group Foot & Ankle at Winter Park Winter Park Florida

Sponsors (3)

Lead Sponsor Collaborator
ULURU Inc. Military Technology Enterprise Consortium (US), Naval Medical Research Center

Country where clinical trial is conducted

United States, 

References & Publications (3)

Han G, Ceilley R. Chronic Wound Healing: A Review of Current Management and Treatments. Adv Ther. 2017 Mar;34(3):599-610. doi: 10.1007/s12325-017-0478-y. Epub 2017 Jan 21. — View Citation

Schaper NC, van Netten JJ, Apelqvist J, Bus SA, Hinchliffe RJ, Lipsky BA; IWGDF Editorial Board. Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3266. doi: 10.1002/dmrr.3266. — View Citation

Wound Care Awareness Week Highlights of the Chronic Wound Epidemic in U.S. Businesswire.com/news/home/20160607006326/en/Wound-Care-Awareness-Week-Highlights-Chronic-Wound. Accessed 11/5/2020.

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of wound closure Compare rate of complete wound healing in diabetic foot wounds between the two study groups 12 weeks
Secondary Wound healing trajectories and time to wound closure Evaluate differences in wound healing trajectories and time to wound closure between the two study groups 12 weeks
Secondary Adverse Events Safety as indicated by adverse events (new or worsening conditions) and frequency of wound infections 12 weeks
Secondary Subject Satisfaction Evaluate subject satisfaction of wound care products based on "Research subject satisfaction survey" completed at the end of study (8 questions total using a 7 point Likert scale). 12 weeks
Secondary Wound pain Compare differences in pain between the groups based on results of a validated 10 point "Visual Analogue Pain Scale" completed at each visit by all subjects. More pain is indicated by higher scores. 12 weeks
Secondary Quality of Life while living with a wound Compare differences in quality of life between the groups based on results of completed validated "Wound Quality of Life Questionnaire for Chronic Wounds" (17 questions total, answering a 5 point scale [not at all to very much], results from answers based on formula) 12 weeks
Secondary Clinician Acceptability Based on clinician survey completed at end of study (8 questions total, multiple choice or 7 point Likert scale) 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04497805 - Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers Phase 2
Withdrawn NCT03675269 - Adjunctive Hyperbaric Oxygen Therapy (HBOT) for Lower Extermity Diabetic Ulcer: N/A
Completed NCT04624516 - Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence N/A
Not yet recruiting NCT06439667 - VIRTUALLY SUPERVISED TELE-EXERCISE PLATFORM FOR ACCELERATING PLANTAR WOUND HEALING
Recruiting NCT05608187 - Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers Phase 2
Not yet recruiting NCT06437028 - Evaluating the Efficacy of Perinatal Membrane Allografts for the Treatment of Diabetic Foot Ulcers. N/A
Not yet recruiting NCT06278935 - Lifestyle Tailored Offloading for Diabetic Foot Ulcers N/A
Withdrawn NCT05024656 - AmnioExcel® Plus vs SOC in the Management of Diabetic Foot Ulcers N/A
Terminated NCT02202668 - Transcutaneous Raman Spectroscope (TRS) Analyses of Diabetic Foot Ulcers N/A
Terminated NCT01966380 - Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia Phase 2
Completed NCT01951768 - Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection Phase 4
Completed NCT01657474 - Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers N/A
Active, not recruiting NCT00389636 - TheraGauzeā„¢ Alone and Regranex®Gel 0.01% Plus TheraGauzeā„¢ in the Treatment of Wagner Stage I Diabetic Foot Ulcers N/A
Completed NCT01181440 - Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers Phase 3
Enrolling by invitation NCT05888259 - Plantar Pressure Distribution in Diabetic Foot Ulcer N/A
Completed NCT04054804 - Digital Foot Check by Using the D-Foot, a New Software
Not yet recruiting NCT05877378 - Efficacy of PICO Single-use System in Chronic Ulcers N/A
Recruiting NCT06037369 - The Short Message-based Customized Standardized N/A
Completed NCT03312595 - Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU) N/A
Recruiting NCT04564443 - A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot N/A